The Lipodystrophy Syndrome as a Risk Marker for Cardiovascular Disease in Patients with HIV/AIDS Treated with HAART by Pereira, Valdelias Xavier et al.
InternatIonal archIves of MedIcIne
Section: cardiology
Issn: 1755-7682 
1
2015
Vol. 8 No. 78
doi: 10.3823/1677
iMedPub Journals
http://journals.imed.pub
© Under License of Creative Commons Attribution 3.0 License This article is available at: www.intarchmed.com and www.medbrary.com 
Abstract
Introduction: The classic risk factors for cardiovascular disease in 
healthy individuals are well known, however, it lacks in the literature 
the mechanisms that predicts cardiovascular disease in the population 
living with HIV-AIDS treated with HAART and presenting syndrome 
lipodystrophy. We aimed to investigate the risk of cardiovascular di-
sease in HIV-AIDS patients treated with HAART and lipodystrophy 
syndrome.
Methods: A search was performed in Medline, SciELO, Lilacs and 
Cochrane using the intersection between the keywords: "cardio-
vascular disease", "HIV", "AIDS", "HAART" and "lipodystrophy 
syndrome".
Results: The selected studies demonstrated that metabolic disorders 
such as hyperlipidemia, central adipose hypertrophy and peripheral 
lipoatrophy, besides the metabolic syndrome and lipodystrophy are 
maker clear risks of developing cardiovascular disease in these indi-
viduals.
Conclusion: The metabolic alterations in HIV-AIDS treated with 
HAART and presenting lipodystrophy syndrome may potentiate the 
development of cardiovascular diseases.
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Background 
The introduction of antiretroviral therapy in high-
power highly active antiretroviral therapy (HAART) 
has resulted in the reduction of mortality associated 
with acquired immunodeficiency syndrome (AIDS) 
in developed countries and in Brazil, despite the in-
creased number of individuals with AIDS in develo-
ping countries [1-4].
However, as a result of this treatment, other 
complications arose, including a metabolic disor-
der called lipodystrophy syndrome (SLD), which is 
characterized by changes in body fat distribution 
(increased waist circumference and breasts, fat ac-
cumulation in the neck, jaws especially the cheeks, 
buttocks) and/or metabolic abnormalities (insulin re-
sistance and dyslipidemia). These changes increase 
the risk for cardiovascular disease [4, 5].
Individuals infected with immunodeficiency virus 
(HIV), requiring treatment for decades, leading to 
cumulative exposure, become more vulnerable to 
the side effects of antiretroviral drugs. Moreover, 
drugs used to treat dyslipidemia are not adequa-
tely studied in relation to patients who use the 
HAART drugs. Some of them should be used with 
caution, because they affect the serum concentra-
tion of the antirretroviral drugs [6, 7]. Additonally, 
the current epidemiological transition shows that a 
diet rich in saturated fats associated with physical 
inactivity is a risk factor for cardiovascular diseases 
[8, 9].
Objective
In this sense, this study aimed to investigate the 
risks of cardiovascular disease in HIV-AIDS patients 
treated with HAART and lipodystrophy syndrome.
Method
Search and selection strategy
Revisions were made between September 2012 and 
January 2013. The following database were used: 
MEDLINE (via PubMed), SciELO , Lilacs and Cochra-
ne. We used the following keywords: "cardiovas-
cular disease", "HIV", "AIDS" and "lipodystrophy 
syndrome". The keywords were defined according 
to the Medical Subject Headings (MeSH).
Studies were selected by one researcher and su-
pervised by a senior researcher. Based on titles and 
abstracts, the manuscripts not clearly related to the 
topic were excluded. 
Studies that did not show full text or summary 
in English between 2001 and 2011 and literature 
reviews were excluded. Inclusion criteria considered 
clinical trials and basic studies investigating the risk 
of cardiovascular disease in individuals with HIV/
AIDS. All selected titles and abstracts were submit-
ted to a final review, which considered the inclusion 
criteria.
Results
The electronic search yielded a total of 1425 re-
ferences. Among these references, the first elimi-
nation resulted in the exclusion of 1297 titles and 
abstracts, which were not clearly related to the 
subject of review. The titles of the remaining 128 
abstracts were submitted to a final review, which 
took into account the inclusion criteria. The inves-
tigation of reference lists confirmed the absence of 
relevant documents. Summaries of the six studies 
were selected. Table 1 shows the risk of occurren-
ce of cardiovascular diseases, the main results and 
conclusions of the studies included. (Table1).
Discussion
The analysis of texts selected for this review indi-
cated that plurimetabolic changes are considered 
risk factors for developing cardiovascular disease 
in the population studied. Moreover, the lipodys-
trophy syndrome behaved as unequivocal marker 
of risk. The literature also reported how HAART 
influences the metabolic impairment and as a 
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consequence increases the risk of cardiovascular 
alterations.
According to Lomar, HAART has 17 drugs that are 
divided into 4 classes: reverse transcriptase inhibi-
tors nucleotide analogues (NRTIs), which act on the 
enzyme reverse transcriptase, incorporating DNA 
into the virus and creating chain. It induces the de-
fective chain and prevents the virus from reprodu-
cing; inhibitors of reverse transcriptase-nucleotide 
analogues (NNRTIs), which directly block the action 
of the enzyme, its propagation and development 
of the infestation in the body; protease inhibitors 
(PI), which prevents the production of new copies 
of HIV-infected cells and fusion inhibitors (PI) which 
prevents the entry of the virus into the cell [10].
Martinez et al, showed that the advent of HAART 
increases the possibility of viral eradication, but stu-
dies have demonstrated the impossibility of comple-
te removal of HIV in the body. In this circumstance, 
considering the current knowledge, patients with 
AIDS have to make use of antiretroviral drugs for 
life, making them indefinitely subjected to the risk 
of cardiovascular disease. Criteria used for initiating 
therapy takes into account the patient's clinical sta-
tus and CD4 + lymphocytes. The viral load measu-
rement is important for the proper choice of the 
various schemes available, as well as for monitoring 
therapeutic outcome, which aims to reduce the viral 
load to below 50 RNA copies/mL, as measured by 
the technique of polymerase chain reaction (PCR) 
or similar [11, 12].
The introduction of antiretroviral therapy has led 
to increased survival of HIV seropositive patients, 
however, it is also related to the advent of new and 
important problems. The authors showed that the 
redistribution of body fat and metabolic abnorma-
lities, called as lipodystrophy syndrome, are among 
the most prevalent and worrisome side effects of 
HAART, besides the high risk of cardiovascular di-
seases [12, 13, 14].
Based on Caron et al, lipid abnormalities found in 
SLD are increased serum levels of triglycerides (TGC) 
and/or total cholesterol at the expense of low-den-
sity lipoprotein and low-density lipoproteins (LDL), 
with a tendency to decrease levels of high density 
lipoproteins and high density lipoproteins (HDL) [15].
Hypertriglyceridemia is mainly due to the high ra-
tes of de novo lipogenesis and delayed clearance of 
Table 1.
Authors and year Main Findings
Lomar AV, 2005 [10] HAART has 17 drugs that are divided into 4 classes: (NRTIs) (NNRTI), (IP) (IF).
Caron  et al., 2003 [15] Lipid abnormalities found in the lipodystrophy syndrome are increased serum levels of 
triglycerides (TGC) and/or total cholesterol at the expense of (LDL), with a trend towards 
decreased levels (HDL).
Galli  et al., 2012 [18] The action of the drug (IP) protease inhibitors, is the main cause of the (IR) insulin resistance.
Sutinen et ai., 2012 [19] Among the anatomic changes of fat redistribution, we identify three groups: lipoatrophy, 
lipohypertrophy and the mixed form.
(DAD) Study Group, 2011 
[23]
The incidence of myocardial infarction or any ischemic vascular event increased with longer 
exposure to HAART.
Law, 2004 [26] There is increased risk of developing cardiovascular disease patients with DM, obesity, co-
infected with hepatitis C. The author reports 16% increase in the incidence of myocardial 
infarction per year of HAART and with Lipo dystrophy syndrome.
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TGC post-prandial period [16]. Studies also revealed 
that a significantly increased proportion of patients 
using IP had elevated serum levels of fasting po-
liprotein B and E, possibly by increased synthesis, 
which could be related to the manifestation of hi-
perlipidemia16. Furthermore, metabolic syndrome 
was present in 18% of HIV patients under HAART 
treatment, especially in patients using [IP17]. The 
abnormalities may manifest as glucose intolerance, 
insulin resistance or diabetes mellitus (DM) [15, 17].
Galli and others explain the mechanisms by which 
antiretroviral (ARV) drugs, such as protease inhibi-
tors, that cause insulin resistance, leading to redu-
ced uptake mediated by insulin in adipocytes and 
skeletal muscle glucose by interfering with the trans-
membrane glucose transporters GLUT-4, in addition 
to the effect transcription factor steroid regulatory 
element-binding protein 1c (SREBP-1) affecting glu-
cose metabolism to produce imperfect expressions 
gamma receptor peroxisome proliferator-activated 
(PPAR-gamma) [18].
It is not yet clear whether the loss of bone mi-
neral density is the same syndrome component 
[17]. Avascular necrosis has been considered a SLD 
complication of HIV, since hyperlipidemia and HIV 
infection are known risk factors for osteonecrosis of 
femural head [16, 19].
It was described by Sutinen et al. that among the 
anatomic changes of fat redistribution, it is identified 
three groups: lipoatrophy, the lipohypertrophy and 
mixed forms [19]. The lipoatrophy and lipohypertro-
phy can occur separately or can occur together in 
the same patient [4, 19]. In lipohypertrophy is obser-
ved accumulation of central fat. The fat accumula-
tion can occur in abdomen, neck, back and breasts. 
The abdomen gets distended appearance and fat 
tissue is commonly deposited intra-abdominal or 
between viscera. Increased intra-abdominal pressu-
re may predispose to abdominal hernias that may 
eventually require surgical correction [15, 18, 19].
It has also been studied accumulation of lipids in 
the upper trunk, extending to the armpits in males 
as well as in the anterior cervical region and supra-
pubic in both sexes [19, 20, 21].
The increased volume of the breasts in females 
occurs mainly due to the fat component, it is not 
associated with glandular hypertrophy. In males, 
gynecomastia (glandular hypertrophy) or pseudo-
gynecomastia (fat accumulation) may also occur [12, 
15, 22].
The lipohypertrophy is more associated with pa-
tients with more advanced age at start of treatment, 
higher body mass index and the use of protease 
inhibitors [19].
In lipoatrophy there is a loss of peripheral subcu-
taneous tissue. There is a thinning of the upper and 
lower limbs, the skin becomes thinned and allows 
viewing, almost anatomical, of the superficial blood 
vessels and muscle groups. This picture may give 
the patient a pseudo-athletic image. Evidence of 
vascular design is also often confused with (pseudo-
varices) venous insufficiency [13, 15, 22].
The largest prospective study of cardiovascular 
risk with HAART is the data collection on adverse 
events of anti -HIV drugs (DAD) [23]. Among the 
23,468 participants, 126 (0.5 percent) had a first 
myocardial infarction, the incidence was 3.5 per 
1000. Among these infarctions, 29 percent were 
fatal, which is 6 percent of all deaths in the stu-
dy. There were over 77 events related to coronary 
ischemia, including artery angioplasty or surgery, 
ischemic stroke, and carotid endarterectomy [24]. 
Incidence of myocardial infarction or any ischemic 
vascular event increased with longer exposure to 
HAART (relative risk, 1.26 [confidence interval of 95 
percent, 1.12 to 1.41] per additional year of expo-
sure, P < 0.001). Very few ischemic events occu-
rred to determine the relative risk associated with 
a specific class of antiretroviral drugs or individual 
drugs. Hypercholesterolemia, advanced age, smo-
king, diabetes mellitus, male gender, and a history 
of cardiovascular disease were also associated with 
an increased risk of myocardial infarction [23]. Risk 
of myocardial infarction in relation to duration of 
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antiretroviral therapy was significant, but was rela-
tively low in analyzes which adjusted for increased 
cholesterol levels, suggesting that metabolic abnor-
malities induced by antiretroviral therapy contribu-
ted to increased morbidity observed [23].
Although DAD23 Study Group has found that the 
relative risk of cardiovascular disease increased with 
duration of antiretroviral therapy, the absolute risk 
of cardiovascular disease remain low for most pa-
tients, except those with several other cardiovascu-
lar risk factors [25 ,26]. The metabolic abnormalities 
are associated with increased risk of cardiovascular 
events.
Thus, according to Law et al, HIV positive pa-
tients, with significantly higher prevalence of ele-
vated levels of fasting glucose and triglycerides and 
low HDL cholesterol levels, have increased risk of 
atherosclerosis, coronary heart disease and diabetes 
mellitus (DM)[18,21,26]. The risk of developing dia-
betes is 6 to 10% higher in these patients, and is 
further increased in obese patients co-infected with 
hepatitis C virus or virus family history of DM. These 
authors reported a 16% increase in the incidence 
of myocardial infarction per year of antiretroviral 
therapy [19, 26].
Conclusion
The lipodystrophy syndrome frequently is associated 
with plurimetabolic changes in individuals with HIV/
AIDS treated with HAART and constitute an impor-
tant risk marker for cardiovascular involvement of 
these patients.
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